Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy

被引:1
|
作者
Kaszubski, Jonatan [1 ]
Gagat, Maciej [2 ,3 ]
Grzanka, Alina [2 ]
Wawrzyniak, Agata [4 ]
Niklinska, Wieslawa [5 ]
Lapot, Magdalena [3 ]
Zuryn, Agnieszka [2 ]
机构
[1] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Medicum Bydgoszcz,Vasc Biol Student Res Club, PL-85067 Bydgoszcz, Poland
[2] Nicolaus Copernicus Univ Torun, Fac Med, Dept Histol & Embryol, Coll Med Bydgoszcz, PL-85067 Bydgoszcz, Poland
[3] Mazovian Acad Plock, Fac Med, Coll Med, PL-09402 Plock, Poland
[4] Univ Rzeszow, Inst Med Sci, Coll Med Sci, Dept Histol & Embryol, PL-35310 Rzeszow, Poland
[5] Med Univ Bialystok, Dept Histol & Embryol, PL-15269 Bialystok, Poland
来源
MOLECULES | 2024年 / 29卷 / 22期
关键词
melanoma; rare subtypes of melanoma; mucosal melanoma; uveal melanoma; acral melanoma; cyclin-dependent kinases (CDKs); CDK inhibitors (CDKIs); CDK4/6; CDK7/9; CDK2; ACRAL MELANOMA; UVEAL MELANOMA; DESMOPLASTIC MELANOMA; GENETIC ABERRATIONS; P16; EXPRESSION; MAPK PATHWAY; DISTINCT; CANCER; COMBINATION; PROTEINS;
D O I
10.3390/molecules29225239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma. In recent years, interest in applying CDK inhibitors (CDKIs) in cancer therapy has grown, as they are able to arrest the cell cycle and inhibit cell proliferation. Current studies highlight selective CDK4/6 inhibitors, like palbociclib or abemaciclib, as a very promising therapeutic option, since they were accepted by the FDA for advanced breast cancer treatment. However, cells of every subtype of melanoma do not react to CDKIs the same way, which is partly because of the genetic differences between them. Herein, we discuss the past and current research relevant to targeting various CDKs in mucosal, uveal and acral melanomas. We also briefly describe the issue of amelanotic and desmoplastic types of melanoma and the need to do more research to discover cell cycle dysregulations, which cause the growth of the mentioned forms of cancer.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma
    Julve, Maximilian
    Clark, James J.
    Lythgoe, Mark P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (03) : 351 - 361
  • [2] Cyclin-dependent kinase inhibitors
    Westwell, A
    DRUG DISCOVERY TODAY, 2001, 6 (09) : 491 - 491
  • [3] Cyclin-dependent kinase inhibitors
    Dai, Y
    Grant, S
    CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) : 362 - 370
  • [4] Cyclin-dependent kinase 7 inhibitors in cancer therapy
    Wang, Minmin
    Wang, Tianyu
    Zhang, Xiangyu
    Wu, Xiaoxing
    Jiang, Sheng
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (09) : 813 - 833
  • [5] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Gitig, DM
    Koff, A
    MOLECULAR BIOTECHNOLOGY, 2001, 19 (02) : 179 - 188
  • [6] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Diana M. Gitig
    Andrew Koff
    Molecular Biotechnology, 2001, 19 : 179 - 188
  • [7] Novel cyclin-dependent kinase inhibitors
    Westwell, AD
    DRUG DISCOVERY TODAY, 2001, 6 (13) : 701 - 701
  • [8] INHIBITORS OF CYCLIN-DEPENDENT KINASE AND CANCER
    BIGGS, JR
    KRAFT, AS
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1995, 73 (10): : 509 - 514
  • [9] Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
    Tadesse, Solomon
    Caldon, Elizabeth C.
    Tilley, Wayne
    Wang, Shudong
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (09) : 4233 - 4251
  • [10] Cyclin-dependent kinase inhibitors and hepatocarcinogenesis
    Hui, AM
    Sakamoto, M
    Kanai, Y
    Ino, Y
    Gotoh, M
    Hirohashi, S
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 481 - 485